Production of drug metabolites by human FMO3 in Escherichia coli by Catucci, Gianluca et al.
Catucci et al. Microb Cell Fact           (2020) 19:74  
https://doi.org/10.1186/s12934-020-01332-1
RESEARCH
Production of drug metabolites by human 
FMO3 in Escherichia coli
Gianluca Catucci, Gianfranco Gilardi and Sheila J. Sadeghi*
Abstract 
Background: In the course of drug discovery and development process, sufficient reference standards of drug 
metabolites are required, especially for preclinical/clinical or new therapeutic drugs. Whole-cell synthesis of drug 
metabolites is of great interest due to its low cost, low environmental impact and specificity of the enzymatic reaction 
compared to chemical synthesis. Here, Escherichia coli (E. coli) JM109 cells over-expressing the recombinant human 
FMO3 (flavin-containing monooxygenase isoform 3) were used for the conversions of clomiphene, dasatinib, GSK5182 
and tozasertib to their corresponding N-oxide metabolites.
Results: The effects of NADPH regeneration, organic solvents as well as C-terminal truncations of human FMO3 were 
investigated. Under the optimized conditions, in excess of 200 mg/L of N-oxide metabolite of each of the four drugs 
could be produced by whole-cell catalysis within 24 h. Of these, more than 90% yield conversions were obtained for 
the N-oxidation of clomiphene and dasatinib. In addition, FMO3 shows high regio-selectivity in metabolizing GSK5182 
where only the (Z) isomer is monooxygenated.
Conclusions: The study shows the successful use of human FMO3-based whole-cell as a biocatalyst for the efficient 
synthesis of drug metabolites including regio-selective reactions involving GSK5182, a new candidate against type 2 
diabetes mellitus.
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Clomiphene, Dasatinib, Tozasertib, GSK5182, Regioselectivity
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Background
Human flavin-containing monooxygenase isoform 3 
(hFMO3) is the most important non-cytochrome P450 
Phase I drug metabolizing enzyme in adult human liver, 
catalysing the monooxygenation of a wide variety of 
nucleophilic heteroatom-containing drugs, xenobiotics 
and dietary compounds [1–3]. In the lengthy process of 
drug development, reference standards of drug metabo-
lites under investigation are required for validation of 
their chemical structures as well as pharmacological 
characterization [4, 5]. Nevertheless, such standards are 
generally not available in the case of new therapeutic 
drugs. One option available to pharmaceutical companies 
is chemical synthesis of the drug metabolites however, 
the latter solution is very demanding both in terms of 
time and capital [6]. In addition, although drug metabo-
lites can be directly generated in vitro by enzymes with 
high selectivity, the synthesis on large scale is challeng-
ing due to low catalytic activity and/or protein stabil-
ity, requirement for the expensive cofactor(s) as well as 
low expression of membrane-bound enzymes [6]. In this 
context, the possibility of synthesizing drug metabo-
lites, through a whole-cell system with the inclusion of a 
human enzyme, becomes extremely attractive due to its 
many advantages: low cost, cofactor regeneration, sta-
ble enzyme, large scale application and uncomplicated 
downstream processing [5].
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The main criterion for whole-cell catalysis is the expres-
sion of the target enzyme in its functional form. In this 
paper, human FMO3 over expressed in Escherichia coli 
(E. coli) JM109 [8–10] (using the pJL2 expression vector 
[7]) was employed for whole-cell catalysis experiments 
with four different drug substrates; clomiphene, dasat-
inib, GSK5182 and tozasertib. The chemical structures of 
these drug substrates and the site of their monooxygena-
tion are shown in Fig.  1. Clomiphene is the most com-
monly used non-steroidal fertility medication for woman 
[11, 12] and has recently been shown to be metabolized 
by human FMO3 [13]. Dasatinib, a multi-targeted kinase 
inhibitor is used for the treatment of chronic myelog-
enous leukemia and acute lymphoblastic leukemia [14] 
and FMO3 been shown to be involved in its metabo-
lism [14]. GSK5182, a highly selective inverse agonist of 
estrogen-related receptor γ, is currently under preclini-
cal investigation as a new anti-diabetic agent for type 2 
diabetes mellitus [15]. N-demethylation and hydroxyla-
tion of this drug are carried out by cytochrome P450s 
whereas FMO3 contributes to the GSK5182 N-oxidation 
[16]. Tozasertib (VX-680, MK0457), a pan-aurora kinase 
inhibitor, is under evaluation as an anticancer drug. It is 
metabolised in the human liver via two major pathways 
one of which involves the FMO3-mediated N-oxidation 
[17, 18].
In this work, the effect of different chemicals on 
NADPH regeneration as well as organic solvents, on 
the overall conversion of the high value metabolites of 
the above-mentioned drugs was investigated. Moreover, 
hFMO3 is anchored to the ER membranes through its 
C-terminus and therefore the effect of several trunca-
tions at the C-terminal on its whole-cell over expression 
and activity were also investigated.
Fig. 1 The chemical structures of the four drugs studied in this work including the E- and Z-isomers. The monooxygenation site of each compound 
is highlighted in red
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Results and discussion
Compounds promoting NADPH formation
In the first set of experiments and in order to carry out 
the optimization of the different parameters involved in 
whole-cell biotransformations, sufficient biomass was 
produced as outlined in methods and materials with 
the overexpression of human FMO3 in E. coli JM109. 
One of the most important bottlenecks in using flavo-
enzymes for the production of drug metabolites is their 
reliance on the expensive NADPH cofactor and therefore 
this parameter was tackled first. For economically effi-
cient utilisation of human FMO3, the consumed reduced 
equivalents have to be regenerated. This can be done by 
the addition of one or more enzymes to the reaction but 
a much simpler method is the use of whole-cells. Previ-
ous studies have indicated that using a whole-cell system, 
the naturally existing cellular metabolic pathways can 
be exploited for the regeneration of this cofactor [19]. 
Moreover, in the specific case of FMO enzymes, Hanlon 
et al. [20] have demonstrated that addition of both citrate 
and  NADP+ to the whole-cell is necessary for full activ-
ity of these enzymes. We therefore proceeded with test-
ing citrate and  NADP+ in our experimental set up which 
includes both a different bacterial strain (E. coli JM109 
versus BL21 DE3 GOLD) and FMO clone (pJL2 [7] versus 
pEamTA).
Figure  2 summaries the NADPH regeneration experi-
ments carried out with the E. coli JM109 cells. As can be 
seen in the figure, a faster regeneration rate was obtained 
in the presence of both  NADP+ and citrate/MgCl2 com-
pared with either  NADP+ or citrate/MgCl2 alone, as 
also demonstrated by Hanlon et  al. [20]. We also tested 
the addition of glucose and although an improvement in 
NADPH regeneration was observed (Fig. 2, asterisks), it 
was not as pronounced as that already observed in the 
presence of  NADP+ and citrate/MgCl2. Therefore, all 
subsequent whole-cell catalyses were carried out in the 
presence of both  NADP+ and citrate/MgCl2.
For the whole-cell catalyses experiments two controls 
were also carried out to confirm that only cells express-
ing the hFMO3 protein were responsible for the products 
observed: (a) conversion using non-transformed E. coli 
JM109 cells resulted in no detectable product within 24 h; 
(b) conversion using the supernatant of the pelleted cells 
also resulted in no detectable product after 24 h, proving 
the integrity of the bacterial cells (data not shown).
The second parameter to be considered was the 
amount of drug to be employed in the whole-cell reac-
tions. In biocatalysis, it has been shown that depending 
on the substrate concentration one can get either higher 
product or lower conversions due to product inhibitory 
effects. Like other drug metabolizing enzymes, majority 
of known substrates of hFMO3 are hydrophobic com-
pounds with low solubility in aqueous buffers. The latter 
observation leads to a limitation in the enzymatic effi-
ciency of this drug metabolizing enzyme. One solution 
to overcome this problem is the use of water miscible 
organic solvents with higher polarity index to develop 
mono- or biphasic media for efficient biocatalysis [21].
To this end, ten different solvents were tested for the 
whole-cell production of tamoxifen N-oxide within 5 h as 
described in “Methods” section. Tamoxifen, a breast can-
cer therapeutics and known substrate of human FMO [8, 
22], is soluble in organic solvents but insoluble in water 
(solubility is < 0.01%, 20 °C). Within our lab we routinely 
employ this drug as a marker substrate for the activ-
ity of purified human FMO enzymes [8] and therefore it 
was used to investigate the effect of different solvents on 
conversion yields. Nonetheless, the results obtained with 
the selected solvents demonstrated not only a decrease 
in conversion yields but also no correlation between the 
polarity index of the solvents and the observed percent-
age conversions (Additional file 1: Table S1).
Effect of human FMO3 truncations on whole‑cell catalysis
Another factor to be considered was the expression 
level of human FMO3 in the bacterial system, as higher 
expression levels in whole-cells would most probably 
improve the product titre. Human FMO3 is a membrane 
associated protein and difficult to overexpress in bacte-
rial cells as many other membrane-bound proteins [23]. 
In order to improve the solubility of human FMO3, we 
had previously reported the construction of three dif-
ferent C-terminal truncations of this protein with the 
deletion of 16, 27 and 39 amino acids by site-directed 
mutagenesis resulting in variants 516X, 505X and 493X, 
Fig. 2 NADPH regeneration measured spectrophotometrically at 
340 nm using recombinant E. coli JM109 cells in the presence of 
different combinations of 0.3 mM  NADP+, 50 mM citrate/10 mM 
 MgCl2 (without any substrate) and glucose (50 mM). Experiments 
were performed three times and the error bars represent the 
standard deviation obtained from the three replicates. *P  <  0.001 
compared to control (cells alone with no other additions) at the 
same time point; Statistical analyses were carried out using One-way 
ANOVA followed by Student–Newman–Keuls post hoc test
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respectively [24]. Whereas the majority of the full-length 
human FMO3 was found in the membrane-bound frac-
tion, the two more conservative truncations, 516X and 
505X, although not completely detached from the mem-
brane were found in the cytosolic fraction. Finally, for the 
most extreme truncation, 493X, was mainly cytosolic as a 
consequence of the higher solubility of the resulting trun-
cated hFMO3 protein.
The above improvement of the cytosolic expression 
of the truncated variants of human FMO3 was initially 
taken as a positive result, thought to favour protein over-
expression in E. coli and as a result the conversion yields 
of the metabolites. In order to prove the latter hypoth-
esis, the three truncated FMO3 proteins were expressed 
in E. coli and used for whole-cell catalysis and produc-
tion of the test metabolite, tamoxifen N-oxide. The reac-
tions were performed at 37  °C for 24  h and the results 
obtained are summarized in Table  1. As can be seen in 
the table and contrary to our hypothesis, the C-termi-
nally truncated enzymes demonstrated a drastic decline 
in biocatalysis of tamoxifen when compared to the mem-
brane-bound human FMO3. More in depth studies are 
required to ascertain as to why the more soluble enzyme 
is not favoured in the whole cell biocatalysis. However, 
similar results were reported by Winker’s group [5] when 
they attempted to solubilize human FMO2 and use it as 
a whole-cell catalyst. They concluded that the deletion 
of several amino acids at the C-terminal of FMO2 might 
have affected the protein’s folding and/or stability.
Whole‑cell catalysis of clomiphene, tozasertib, dasatinib 
and GSK5182
The whole-cell set up was finally employed for the pro-
duction of the human FMO3 drug metabolites as 
described in “Methods” section. The data obtained for 
the 4 different drugs are shown in Fig.  3 and summa-
rized in Table 2. In the case of dasatinib N-oxygenation, 
more than 90% of the parent drug was transformed to the 
metabolite within 24 h. Dasatinib N-oxide was identified 
and confirmed by LC–MS (Additional file 1: Fig. S1).
Commercial clomiphene is a mixture of two geometric 
isomers, (E)- and (Z)-clomiphene [13]. The results dem-
onstrate that both of these two isomers can be converted 
to the N-oxide product by FMO3-based whole-cell bioca-
talysis, with an overall conversion yield of 93% (Table 2). 
In this case, the human FMO3 shows no selectivity in 
its activity. The identification of the N-oxide products of 
clomiphene have been previously reported by our group 
[16].
A more interesting result was obtained for GSK5182 
where hFMO3 shows high regio-selectivity by convert-
ing only one of the two isomers (parent drug sold with 
an isomer ratio of 1:1), the Z-isomer, to its corresponding 
N-oxide product as shown in Fig. 4. There are currently 
no commercially available standards and therefore the 
N-oxide product identification was performed by LC–
MS [16]. An overall conversion of 98.4% was obtained for 
this drug which corresponds to the maximum theoretical 
conversion yield (Fig. 4 and Table 2).
Out of the four drugs tested, the lowest conver-
sion yield was obtained with tozasertib. The N-oxide 
product had also been identified by LC–MS and 
reported by our group previously [25]. In this case, the 
Table 1 Effect of  the  different C-terminal truncations 
of  human FMO3 on  the  conversion of  the  test substrate, 
tamoxifen, compared to the full-length protein
The experiments were carried out in triplicates. Data represent the mean 
(± standard deviation, SD) of the three independent experiments
FMO3 Conversion (%)
Full-length 78.0 ± 2.0
516X 4.0 ± 0.2
505X 10.0 ± 0.4
493X 1.0 ± 0.1
Fig. 3 Human FMO3-based whole-cell conversion of GSK5182, 
clomiphene, tozasertib and dasatinib to their corresponding N-oxide 
metabolites within a 24-h period. Experiments were performed in 
triplicates with the error bars representing the standard deviation. 
No metabolite was detected in the control experiments within 24 h 
(non-transformed E. coli JM109 cells in the presence of the four 
different substrates)
Table 2 Conversion yields for  different substrates 
of hFMO3 using whole-cell catalysis at 37 °C within 24 h
Data represent the mean (± standard deviation, SD) of three independent 
experiments
Substrate N‑oxide product (mg/L) Conversion (%)
Clomiphene 392.4 ± 1.7 93.0 ± 0.4
Dasatinib 499.0 ± 3.5 99.0 ± 0.7
GSK5182 208.8 ± 1.5 98.4 ± 0.7
Tozasertib 201.8 ± 2.9 42.0 ± 0.6
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biotransformation to the N-oxide metabolite reached 
only 42%. One possible explanation for this obser-
vation is the lower solubility of the tozasertib parent 
drug compared to the other tested drugs [18].
Conclusions
Many approved pharmaceutical drugs and drug can-
didates contain nitrogen, a soft nucleophile that is 
metabolized by human FMO3. The data presented 
demonstrate the successful use of recombinant human 
FMO3 in a whole-cell set up as a biocatalyst for drug 
metabolite synthesis. This whole-cell system with the 
specified cofactor recycling of human FMO3, allowed 
for the production of high value drug metabolites 
from clomiphene, dasatinib and GSK5182, with con-
version yields ranging from 93.0 to 99.0%, corre-
sponding to 200  mg of each product per liter of cells 
within a 24-h period. Tozasertib conversion reached 
only around 40%. These drugs span a whole range of 
chemical structures as well as varied functionality i.e. 
from promising diabetes drug to cancer therapeutics. 
More importantly, the regio-selectivity of this human 
enzyme is also demonstrated in its reaction with 
GSK5182, currently available only as a mixture of the 
two isomers.
Finally, this whole-cell set up, combination of recom-
binant E. coli JM109 with human FMO3, is a promis-
ing “green” and cost-effective tool for generation of 
reference drug metabolite standards not only for drug 
metabolism studies but also for use during drug dis-
covery and development process.
Methods
Chemicals
Acetonitrile, ampicillin, flavin adenine dinucleotide diso-
dium salt hydrate (FAD), benzydamine hydrochloride, 
tamoxifen, clomiphene citrate salt, NADPH, Isopropyl-ß-
D-thiogalactopyranoside (IPTG), IGEPAL (octylphenoxy 
poly(ethyleneoxy)ethanol) and potassium phosphate 
were purchased from Sigma-Aldrich.
The drugs under study were purchased from differ-
ent sources, clomiphene from DBA Italia (Italy); toza-
sertib from Aurogene (Rome, Italy); dasatinib from 
Selleck Chemicals (Houston, USA) and GSK5182 
(4-[1-[4-[2-(Dimethylamino)ethoxy]phenyl]-5-hydroxy-
2-phenylpent-1-enyl]phenol) (with isomer ratio of 1:1, 
E:Z) from Glaxosmithkline (UK).
Whole‑cell preparation
Human FMO3 (with a C-terminal His tag) inserted 
into pJL2 was expressed in E. coli JM109 as previously 
reported [8, 24] and exploited for whole-cell catalysis. 
Non-transformed E. coli JM109 cells were used as the 
negative control. 4 L cultures of the human FMO3 in ter-
rific broth (eight 2L Pyrex glass Erlenmeyer flasks each 
with 500  mL media) were inoculated with an overnight 
inoculum of the recombinant E. coli JM109 to generate 
the necessary biomass for whole-cell catalysis studies. 
The cells were incubated at 37 °C with 200 rpm agitation 
until an  OD600 of 0.8 was reached before induction with 
1 mM IPTG. The cells were then grown at the lower tem-
perature of 24 °C and agitated at 180 rpm for 24 h after 
which time they were centrifuged at 4000×g for 10 min. 
Any remaining growth media was removed by exchang-
ing with 100  mM phosphate buffer pH 8.5. Finally, the 
resulting pellet was stored at − 20 °C until use.
C‑terminal truncations of human FMO3
The previously published hydropathy plot of the amino 
acid sequence of hFMO3 [24] had identified the C-ter-
minus as a membrane anchor and consequently three 
C-terminally truncated hFMO3 constructs (516X, 505X 
and 493X) were generated in our lab [24]. In the current 
work, these 3 proteins were heterologously expressed in 
E. coli JM109 in the same way as the full-length protein 
in order to evaluate whether any of these truncated pro-
teins (higher cytosolic versus membrane-bound) could 
improve the conversion yields of the substrates in whole-
cell catalysis.
Chemicals tested for regeneration of NADPH
Human FMO3 is an NADPH-dependent enzyme and 
therefore due to the high price of this cofactor it is vital 
that a regeneration system is set up for preparative 
Fig. 4 The superimposed HPLC chromatograms of GSK5182 (blue 
trace) and its conversion to its N-oxide by human FMO3 (red trace). 
The enzyme shows regioselectivity only metabolizing the Z-isomer 
(retention time of 5.5 min), while the E-isomer is untouched 
(retention time of 7.5 min). The N-oxide product (retention time of 
9.3 min) was identified by LC–MS
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applications. The previously reported NADPH regener-
ating system  NADP+/citrate/MgCl2 [20] was therefore 
investigated and the effects of the addition of each of 
the latter compounds, alone and/or in combination, on 
NADPH regeneration was monitored at 340 nm. More-
over, the simple addition of glucose (50  mM) was also 
tested. The amount of NADPH produced in each case 
was determined using the molar extinction coefficient 
value of 6.22 mM−1cm−1.
Effect of various organic solvents
Ten organic solvents with different polarity index were 
selected in order to test whether any of them would 
result in an increase in conversion yields of tamoxifen. A 
typical reaction mixture contained the recombinant cells 
 (OD600 of 10), 2 mM tamoxifen, 0.3 mM  NADP+, 50 mM 
tri-sodium citrate, 10 mM  MgCl2 in 100 mM phosphate 
buffer pH 8.5 with 10% (v/v) organic solvent in a total 
volume of 8 mL. The reactions were carried out at 37 °C, 
200  rpm for 5  h after which time they were terminated 
by the addition of ice-cold acetonitrile followed by HPLC 
analysis. Control experiments were performed in the 
absence of organic solvent using phosphate buffer pH 8.5.
HPLC analyses of metabolites
For each of the FMO3-mediated whole-cell catalyses, cell 
pellet  (OD600 = 10) was resuspended in 8 mL of 100 mM 
phosphate buffer pH 8.5 (filter-sterilized). The reac-
tion was then initiated by mixing of the test substrates 
(1 mM final concentration),  NADP+ (0.3 mM final con-
centration), tri-sodium citrate (50  mM final concentra-
tion),  MgCl2 (10  mM final concentration) to the cell 
suspension. The reaction mixture was incubated at 37 °C, 
200  rpm. 200 μL samples were drawn at certain time 
points, mixed with 200 μL acetonitrile and centrifuged 
for 5  min at 16,300×g. The resulting supernatant was 
subsequently analysed by HPLC (Agilent-1200, Agilent 
Technologies, USA) equipped with 4.6 × 150  mm 5  μm 
Eclipse XDB-C18 column, at 22 °C.
Two different controls were carried out to confirm 
that the N-oxide metabolites were indeed the result of 
hFMO3 catalysis. In the first control, non-transformed 
E. coli JM109 were used in the presence of tamoxifen 
as the substrate. The second control was carried out in 
order to confirm that the cells were intact and there was 
no enzyme leakage. In this case, the pellet (transformed 
E. coli JM109-hFMO3) was resuspended in potassium 
phosphate buffer pH 8.5 and centrifuged at 16,300×g for 
5 min, the resulting supernatant was used for the enzy-
matic reaction again in the presence of tamoxifen as 
described above.
In order to systematically analyse the products of 
the whole-cell reactions the same mobile phase of 
acetonitrile (A) and 0.1% formic acid (B) in water was 
used for the separation of all products from their cor-
responding parent drug. In all cases an isocratic elution 
was performed for the HPLC analyses. This meant that 
only the ratios of the two different mobile phases were 
modified for each of the 4 drugs; clomiphene (34% A and 
66% B, monitored at 290 nm) [16], dasatinib (22% A and 
78% B, monitored at 320 nm), GSK5182 (25% A and 75% 
B, monitored at 280 nm), and tozasertib (20% A and 80% 
B, monitored at 250 nm). Tamoxifen which was used for 
in the organic solvent as well as the truncated human 
FMO3 experiments, was also separated from its N-oxide 
product using the same mobile phases (40% A and 60% B 
and monitored at 276 nm). All measurements were per-
formed in triplicates.
N-oxide metabolites of GSK5182 and tozasertib are not 
commercially available however, these metabolites have 
been previously identified and confirmed by mass spec-
trometry analysis by our group [16, 18].
Identification of dasatinib N‑oxide by LC–MS
The identification of the dasatinib N-oxide product 
was performed in collaboration with Ion Source & Bio-
technologies Srl (Milan, Italy) as reported previously 
for the GSK5182 using an Orbitrap mass spectrom-
eter (ThermoFisher, San Jose, USA) working in positive 
ion mode [16]. Spectra acquisition was conducted in 
the 40–3500  m/z range. ESI capillary voltage was kept 
at 1500 V, SACI surface voltage was set to 47 V, drying 
gas: 2 L/min, nebulizer gas at 80 psi and temperature 
at 40  °C. Fragment and precursor ions were isolated 
through an ion trap and in order to obtain the fragments 
with high accurate m/z ratio (resolution 15,000, m/z 
error < 10 ppm) the Orbitrap mass analyser was used.
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